SCHEMBL1165753

SCHEMBL1165753

CC1(C)OC(=O)c2ccc(CBr)cc2O1

nearest known ligand 0.36

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.36
ALOX15 P16050 1/20 0.35
ALOX12 P18054 1/20 0.35
MAOB P27338 9/20 0.35
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 5/20 0.33
KDM4E B2RXH2 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
GLA P06280 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
KMT2A Q03164 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29225754 0.87 TSHR (0.36) TSHRALOX15ALOX12LMNASMN1; SMN2
SCHEMBL2868883 0.85 TSHR (0.38) TSHRALOX15ALOX12MAOBLMNA
SCHEMBL12960368 0.84 CNR2 (0.40) TSHRALOX15ALOX12MAOBLMNA
SCHEMBL14879974 0.80 AKR1B1 (0.48) TSHRLMNAALDH1A1KDM4ETDP1
SCHEMBL22924626 0.80 TDP1 (0.43) LMNASMN1; SMN2ALDH1A1L3MBTL1TDP1
SCHEMBL14898315 0.80 L3MBTL1 (0.38) TSHRALOX15ALOX12MAOBLMNA
SCHEMBL11630777 0.79 ALOX15 (0.51) TSHRALOX15ALOX12SMN1; SMN2ALDH1A1
SCHEMBL3526681 0.78 ALDH1A1 (0.44) TSHRMAOBLMNAALDH1A1KDM4E
SCHEMBL4956149 0.77 CYP3A4 (0.52) ALOX15ALOX12MAOBLMNASMN1; SMN2
SCHEMBL1165494 0.76 ALDH1A1 (0.45) TSHRMAOBLMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4562015-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 EP disclosed
CN-118108676-B Benzenesulfonamide compound, pharmaceutical composition and application thereof 中国药科大学 2025-02-07 CN disclosed
CN-118108676-A Benzenesulfonamide compound, pharmaceutical composition and application thereof 中国药科大学 2024-05-31 CN disclosed
US-11970448-B2 Monomers capable of dimerizing in an aqueous solution, and methods of using same CORNELL UNIVERSITY (US) 2024-04-30 US disclosed
WO-2024026481-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
US-20200354319-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME UNIV CORNELL (US) 2020-11-12 US disclosed
US-20140194383-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CORNELL UNIVERSITY (US) 2014-07-10 US disclosed
US-20140194383-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CORNELL UNIVERSITY (US) 2014-07-10 US disclosed
US-8691980-B2 Salicylic acid derivatives with fluorophores and method of making and using the same NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY (TW) 2014-04-08 US disclosed
US-8691980-B2 Salicylic acid derivatives with fluorophores and method of making and using the same NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY (TW) 2014-04-08 US disclosed
US-7666863-B2 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases VIROPHARMA INCORPORATED (US) 2010-02-23 US disclosed
US-20090281336-A1 BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES SAHA ASHIS K 2009-11-12 US disclosed
WO-2009080821-A2 RECEPTOR TARGETING LIGANDS GIULIANI INTERNATIONAL LIMITED (IE) 2009-07-02 WO disclosed
US-20080274947-A1 Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-11-06 US disclosed
US-20070231318-A1 BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES SAHA ASHIS K 2007-10-04 US disclosed
US-7265152-B2 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases VIROPHARMA INCORPORATED (US) 2007-09-04 US disclosed
EP-1581207-A4 BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES VIROPHARMA INC (US) 2007-07-25 EP disclosed
EP-1581207-A2 BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES Viropharma Incorporated (US) 2005-10-05 EP disclosed
US-20040162318-A1 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases VIROPHARMA INCORPORATED 2004-08-19 US disclosed
WO-2004041201-A2 BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES VIROPHARMA INCORPORATED (US) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11970448-B2 Monomers capable of dimerizing in an aqueous solution, and methods of using same CALCOCO2, MDN1, MBNL1 TSHR 3797/4885ALOX15 4127/4885ALOX12 3814/4885
US-20070231318-A1 BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES BBOX1, HAVCR2, CYP2E1 TSHR 4825/4885ALOX15 440/4885ALOX12 334/4885
US-20080274947-A1 Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia CYP46A1, GPR119, DHCR7 TSHR 1869/4885ALOX15 193/4885ALOX12 287/4885
US-20090281336-A1 BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES BBOX1, HAVCR2, CYP2E1 TSHR 4825/4885ALOX15 440/4885ALOX12 334/4885
US-20200354319-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CALCOCO2, MDN1, MBNL1 TSHR 3797/4885ALOX15 4127/4885ALOX12 3814/4885
US-20140194383-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CALCOCO2, MDN1, MBNL1 TSHR 3797/4885ALOX15 4127/4885ALOX12 3814/4885
US-20040162318-A1 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases BBOX1, HAVCR2, CYP2E1 TSHR 4825/4885ALOX15 440/4885ALOX12 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.